FrancophonIA/ELRC3.0 huggingface dataset:
English: Table 4: Demographic and baseline disease characteristics of antiretroviral treatmentexperienced HIV-1 infected adult subjects in study GS-US-183-0145
Danish: Tabel 4: Demografiske og sygdomskarakteristika ved baseline for antiretroviralbehandlingserfarne, hiv-1-inficerede voksne personer i studie GS-US-183-0145 Elvitegravir + baggrundsregime n = 351
English: Co-administration of Vitekta with medicinal products that are strong inducers of CYP3A is contraindicated as the expected decrease in plasma concentrations of elvitegravir can lead to loss of therapeutic effect and possible development of resistance to elvitegravir (see section 4.3).
Danish: Samtidig administration af Vitekta og lægemidler, der er stærke inducere af CYP3A er kontraindiceret, da det forventede fald i plasmakoncentrationer af elvitegravir kan forårsage svigtende terapeutisk virkning og mulig udvikling af resistens over for elvitegravir (se pkt.
English: Fosamprenavir (700 mg twice daily)
Danish: Fosamprenavir (700 mg to gange dagligt)
English: Limited data from population pharmacokinetic analysis (n = 56) indicated that hepatitis B and/or C virus infection had no clinically relevant effect on the exposure of boosted elvitegravir.
Danish: Samtidig infektion med hepatitis B- og/eller hepatitis C-virus Ufuldstændige data fra en populationsfarmakokinetisk analyse (n = 56) viste, at infektion med hepatitis B- og/eller hepatitis C-virus ikke medførte klinisk relevant ændring i eksponeringen for
English: No dose adjustment is required when Vitekta is co-administered with ritonavir-boosted atazanavir plus telaprevir.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med ritonavir-boosted atazanavir plus telaprevir.
English: If you are also taking other medicines:
Danish: Hvis De har glemt at tage en dosis:
English: The following pack size is available: outer cartons containing 1 bottle of 30 film-coated tablets.
Danish: Fås i en pakning, der indeholder 1 tabletbeholder med 30 filmovertrukne tabletter.
English: In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Danish: Hos hiv-inficerede patienter med svær immuninsufficiens kan der ved påbegyndelse af CART opstå en inflammatorisk reaktion på asymptomatiske eller latente opportunistiske mikrober, som kan forårsage alvorlig sygdom eller forværring af symptomer.
English: Co-administration of elvitegravir and rilpivirine is not expected to change elvitegravir plasma concentrations, therefore no dose adjustment of Vitekta is required.
Danish: Samtidig administration af elvitegravir og rilpivirin forventes ikke at ændre plasmakoncentrationen af elvitegravir.
English: Among subjects with a genotypic sensitivity score > 1, 57% and 56% had HIV-1 RNA < 50 copies/mL at week 48 in the elvitegravir and raltegravir treatment arms, respectively.
Danish: Blandt personer med en følsomhedsscore for genotype > 1 havde 57 % og 56 % hiv-1-rna < 50 kopier/ml ved uge 48 i behandlingsarmene for hhv. elvitegravir og raltegravir.
English: Pharmacotherapeutic group: Antivirals for systemic use, other antivirals, ATC code: J05AX11.
Danish: Farmakoterapeutisk klassifikation: Antivirale midler til systemisk brug; andre antivirale midler.
English: The active substance is elvitegravir.
Danish: Aktivt stof: elvitegravir.
English: 4.2 Posology and method of administration Therapy should be initiated by a physician experienced in the management of HIV infection.
Danish: Behandlingen skal påbegyndes af en læge med erfaring i behandlingen af hiv-infektion.
English: No clinically relevant pharmacokinetic differences due to gender have been identified for boosted
Danish: Der er ikke blevet identificeret klinisk relevante farmakokinetiske forskelle på grund af køn for
English: Gilead Sciences S.r.l.
Danish: Gilead Sciences, S.L.
English: Among subjects with a genotypic sensitivity score of ≤ 1, 76% and 69% had HIV-1 RNA < 50 copies/mL at week 48 in the elvitegravir and raltegravir treatment arms, respectively.
Danish: Blandt personer med en følsomhedsscore for genotype ≤ 1 havde 76 % og 69 % hiv-1-rna < 50 kopier/ml ved uge 48 i behandlingsarmene for hhv. elvitegravir og raltegravir.
English: Table 6: Virologic success by co-administered protease inhibitor in study GS-US-183-0145 at week 48 and week 96 (snapshot analysis)
Danish: Tabel 6: Virologisk success efter samtidigt administreret proteasehæmmer i studie GS-US-183-0145 ved uge 48 og uge 96 (snapshot-analyse)
English: No clinically relevant pharmacokinetic differences due to ethnicity have been identified for boosted
Danish: Der er ikke blevet identificeret klinisk relevante farmakokinetiske forskelle på grund af etnisk
English: No clinically relevant differences in elvitegravir pharmacokinetics were observed between subjects with moderate impairment and healthy subjects.
Danish: Der blev ikke observeret nogen klinisk relevante forskelle i farmakokinetikken for elvitegravir hos personer med moderat nedsat leverfunktion og hos raske personer.
English: No dose adjustment is required when Vitekta is co-administered with buprenorphine/naloxone.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med buprenorphin/naloxon.
English: • nevirapine
Danish: Rilpivirin
English: Green, pentagon-shaped, film-coated tablet of dimensions 8.9 mm x 8.7 mm, debossed with “GSI” on one side of the tablet and “85” on the other side of the tablet.
Danish: Grønne, femkantsformede, filmovertrukne tabletter, der måler 8,9 mm x 8,7 mm, og som på den ene side af tabletten er præget med "GSI" og tallet "85" på den anden side af tabletten.
English: No dose adjustment of Vitekta is required in patients with mild (Child-Pugh Class A) or moderate hepatic impairment (Child-Pugh Class B).
Danish: Dosisjustering af Vitekta er ikke nødvendigt hos patienter med let nedsat (Child-Pugh klasse A) eller moderat nedsat (Child-Pugh klasse B) leverfunktion.
English: Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation via UGT1A1/3 enzymes (minor route).
Danish: Elvitegravir gennemgår oxidativ metabolisme af CYP3A (primært), og glukuronidation via UGT1A1/3-enzymer (i mindre grad).
English: No dose adjustment is required when Vitekta is co-administered with atorvastatin, fluvastatin, pitavastatin or pravastatin.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med atorvastatin, fluvastatin, pitavastatin eller pravastatin.
English: • atazanavir and ritonavir
Danish: • atazanavir og ritonavir
English: No dose adjustment of Vitekta is necessary for patients with mild to moderate hepatic impairment.
Danish: Dosisjustering af Vitekta er ikke nødvendig for patienter med let til moderat nedsat leverfunktion.
English: No dose adjustment is required when Vitekta is co-administered with tenofovir disoproxil fumarate or with emtricitabine.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med tenofovirdisoproxilfumarat eller med emtricitabin.
English: Green, triangle-shaped, film-coated tablet of dimensions 10.9 mm x 10.5 mm, debossed with “GSI” on one side of the tablet and “150” on the other side of the tablet.
Danish: Grønne, trekantsformede, filmovertrukne tabletter, der måler 10,9 mm x 10,5 mm, og som på den ene side af tabletten er præget med "GSI" og tallet "150" på den anden side af tabletten.
English: Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation by UGT1A1/3 enzymes (minor route).
Danish: Elvitegravir gennemgår oxidativ metabolisme af CYP3A (primært), og glukuronidation af UGT1A1/3-enzymer (i mindre grad).
English: No clinically relevant differences in elvitegravir pharmacokinetics were observed between subjects with severe renal impairment and healthy subjects.
Danish: Der blev ikke observeret nogen klinisk relevante forskelle i farmakokinetikken for elvitegravir hos personer med svært nedsat nyrefunktion og hos raske personer.
English: Do not change the dose unless your doctor tells you to. You must always take Vitekta with one of the following combinations of medicines:
Danish: De skal altid tage Vitekta med én af følgende kombinationer af lægemidler:
English: Elvitegravir has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Danish: Elvitegravir er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C).
English: Stavudine: AUC: ↔ Cmax: ↔
Danish: Stavudin: AUC: ↔ Cmax: ↔
English: When your supply of Vitekta starts to run low, get more from your doctor or pharmacist.
Danish: Når De snart ikke har mere af Vitekta, skal De bede om mere fra lægen eller på apoteket.
English: Vitekta film-coated tablets are green, triangle-shaped tablets, debossed on one side with “GSI” and “150” on the other side of the tablet.
Danish: Vitekta filmovertrukne tabletter er grønne, trekantsformede tabletter, som på den ene side er præget med "GSI" og tallet "150" på den anden side af tabletten.
English: Effects on drug levels
Danish: Virkning på lægemiddelkoncentrationer Gennemsnitlig ændring i
English: No dose adjustment of Vitekta is required in patients with mild (Child-Pugh Class A) or moderate hepatic impairment (Child-Pugh Class B) (see sections 4.2 and 5.2).
Danish: Dosisjustering af Vitekta er ikke nødvendig hos patienter med let (Child-Pugh klasse A) eller moderat (Child-Pugh klasse B) nedsat leverfunktion (se pkt.
English: Dose of co-administered ritonavir-boosted protease inhibitor
Danish: Dosis af samtidigt administreret ritonavir-boosted proteasehæmmer
English: No dose adjustment of Vitekta is required for patients with renal impairment.
Danish: Dosisjustering af Vitekta er ikke nødvendig for patienter med nedsat nyrefunktion.
English: elvitegravir.
Danish: Anbefaling vedr.
English: No dose adjustment of Vitekta is required for patients with renal impairment (see section 5.2).
Danish: Dosisjustering af Vitekta er ikke nødvendigt for patienter med nedsat nyrefunktion (se pkt.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150 mg of elvitegravir.
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver filmovertrukket tablet indeholder 150 mg elvitegravir.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 85 mg of elvitegravir.
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver filmovertrukket tablet indeholder 85 mg elvitegravir.
English: Atazanavir/ritonavir and lopinavir/ritonavir have been shown to significantly increase the plasma concentrations of elvitegravir (see section 4.5).
Danish: Det er påvist, at atazanavir/ritonavir og lopinavir/ritonavir forhøjer plasmakoncentrationerne af elvitegravir signifikant (se pkt.
English: This includes medicines and herbal products obtained without a prescription.
Danish: Dette gælder også medicin, som ikke er købt på recept, f.eks. naturlægemidler.
English: Each film-coated tablet contains 85 mg of elvitegravir.
Danish: Hver filmovertrukket tablet indeholder 85 mg elvitegravir.
English: Talk to your doctor if you are taking: • rifabutin, used to treat bacterial infections including tuberculosis
Danish: • rifabutin, der anvendes til at behandle bakterieinfektioner, herunder tuberkulose
English: Refer to the package leaflet for Vitekta 85 mg tablets.
Danish: Der henvises til produktresuméet for Vitekta 85 mg tabletter.
English: Vitekta film-coated tablets are green, pentagon-shaped tablets, debossed on one side with “GSI” and “85” on the other side of the tablet.
Danish: Vitekta filmovertrukne tabletter er grønne, femkantsformede tabletter, som på den ene side er præget med "GSI" og tallet "85" på den anden side af tabletten.
English: Elvitegravir did not show any carcinogenic potential in long-term oral carcinogenicity studies in mice and rats.
Danish: Langvarige orale karcinogenicitetsstudier med elvitegravir viste ikke karcinogenicitet hos mus og
English: Gilead Sciences International Limited Cambridge
Danish: Gilead Sciences Intl Ltd Cambridge
English: There are no data available to make dosing recommendations for co-administration with other doses of lopinavir/ritonavir (see section 4.2).
Danish: Der foreligger ingen data til anbefaling af dosering ved samtidig administration med andre doser af lopinavir/ritonavir (se pkt.
English: The use of Vitekta in children and adolescents has not yet been studied.
Danish: Anvendelsen af Vitekta til børn og
English: Baseline characteristics and treatment outcomes through 96 weeks for study GS-US-183-0145 are presented in Tables 4 and 5 respectively.
Danish: Baselinekarakteristika og behandlingsresultater til og med 96 uger for studie GS-US-183-0145 er
English: BOTTLE AND CARTON LABELLING
Danish: ETIKETTERING PÅ TABLETBEHOLDER OG PAKNING
English: Abacavir (600 mg once daily) Elvitegravir (200 mg once daily) Ritonavir (100 mg once daily)
Danish: Abacavir (600 mg én gang dagligt) Elvitegravir (200 mg én gang dagligt)
English: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Danish: Ætiologien anses dog for at være multifaktoriel (anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, høj Body Mass Index (BMI)).
English: Elvitegravir is primarily metabolised by CYP3A (see section 5.2).
Danish: Elvitegravir metaboliseres primært af CYP3A (se pkt.
English: §Due to inhibition of CYP3A by ritonavir, 25-O-desacetyl-rifabutin exposure is increased.
Danish: §Eksponering for 25-O-desacetyl-rifabutin forhøjes pga. CYP3A-hæmning af ritonavir.
English: Elvitegravir: AUC: ↔
Danish: Fosamprenavir: AUC: ↔
English: Refer to the package leaflet for Vitekta 150 mg tablets.
Danish: Se indlægssedlen til Vitekta 150 mg tabletter.
English: No dose adjustment is required when Vitekta is co-administered with maraviroc.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med maraviroc.
English: No dose adjustment is required when Vitekta is co-administered with ketoconazole.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med ketoconazol.
English: Elvitegravir (125 mg once daily)
Danish: Elvitegravir (125 mg én gang dagligt)
English: When used in combination with atazanavir, the dose of Vitekta should be 85 mg once daily.
Danish: Ved brug i kombination med atazanavir bør dosis af Vitekta være 85 mg én gang dagligt.
English: ANTIRETROVIRALS
Danish: ORALE ANTIKONCEPTIVA
English: Vitekta 85 mg film-coated tablets
Danish: Vitekta 85 mg filmovertrukne tabletter
English: The Summary of Product Characteristics for the co-administered ritonavir-boosted protease inhibitor
Danish: Produktresuméet for den samtidigt administrerede ritonavir-boosted proteasehæmmer skal konsulteres.
English: When used in combination with fosamprenavir, the dose of Vitekta should be 150 mg once daily.
Danish: Ved brug i kombination med fosamprenavir bør dosis af Vitekta være 150 mg én gang dagligt.
English: Vitekta 85 mg film-coated tablets Elvitegravir
Danish: Vitekta 85 mg filmovertrukne tabletter Elvitegravir
English: When used in combination with darunavir, the dose of Vitekta should be 150 mg once daily.
Danish: Ved brug i kombination med darunavir bør dosis af Vitekta være 150 mg én gang dagligt.
English: -21.4% (-73.6% to 30.7%)
Danish: -21,4 % (-73,6 % til
English: There are no data available to make dosing recommendations for co-administration with other doses of atazanavir (see section 4.2).
Danish: Der foreligger ingen data til anbefaling af dosering ved samtidig administration med andre doser af atazanavir (se pkt.
English: Although limited by the small number of female subjects in study GS-US-183-0145, subgroup analysis by gender showed that the rates of virologic success in female subjects at weeks 48 and 96 (HIV-1 RNA < 50 copies/mL) were numerically lower in the elvitegravir treatment arm than in the raltegravir treatment arm. Virologic success rates at week 48 for elvitegravir and raltegravir were 47.5% (28/59) and 62.7% (42/67) (difference: -12.3% [95% CI: -30.1% to 5.5%]), respectively, for female subjects, and 62.3% (182/292) and 56.3% (160/284) (difference: 5.3% [95% CI: -2.5% to 13.2%]), respectively, for male subjects.
Danish: Virologisk successrate ved uge 48 for elvitegravir og raltegravir var hhv. 47,5 % (28/59) og 62,7 % (42/67) (forskel: -12,3 % [95 % CI: -30,1 % til 5,5 %]), for kvinder, og hhv. 62,3 % (182/292) og 56,3 % (160/284) (forskel: 5,3 % [95 % CI: -2,5 % til 13,2 %]) for mænd.
English: When used in combination with lopinavir/ritonavir, the dose of Vitekta should be 85 mg once daily.
Danish: Ved brug i kombination med lopinavir/ritonavir bør dosis af Vitekta være 85 mg én gang dagligt.
English: Missing data during a Week 48 window is between day 309 and 364 (inclusive), week 96 window is between day 645 and 700 (inclusive).
Danish: Seponerede studiemedicin som følge af andre årsager, og sidste tilgængelige hiv-1-rna a Uge 48 vindue er fra dag 309 til 364 (inklusive).
English: No dose adjustment is required when Vitekta is co-administered with rosuvastatin.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med rosuvastatin.
English: No dose adjustment is required when Vitekta is co-administered with methadone.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med methadon.
English: If you take more Vitekta than you should
Danish: Sådan skal De tage Vitekta
English: For use of the 150 mg tablet, please refer to the Summary of Product Characteristics for Vitekta 150 mg tablets.
Danish: Der henvises til produktresuméet for Vitekta 150 mg tabletter for oplysninger om anvendelse af 150 mg tabletten.
English: • darunavir and ritonavir
Danish: • darunavir og ritonavir
English: Psychiatric disorders:
Danish: Tabletkerne:
English: Vitekta 150 mg film-coated tablets Elvitegravir
Danish: Vitekta 150 mg filmovertrukne tabletters Elvitegravir
English: There are no data available to make dosing recommendations for co-administration with other doses of darunavir (see section 4.2).
Danish: Der foreligger ingen data til anbefaling af dosering ved samtidig administration med andre doser af darunavir (se pkt.
English: No dose adjustment is required when Vitekta is co-administered with abacavir.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med abacavir.
English: There are no data available to make dosing recommendations for co-administration with other doses of fosamprenavir (see section 4.2).
Danish: Der foreligger ingen data til anbefaling af dosering ved samtidig administration med andre doser af fosamprenavir (se pkt.
English: Vitekta 150 mg film-coated tablets
Danish: Vitekta 150 mg filmovertrukne tabletter
English: No dose adjustment is required when Vitekta is co-administered with etravirine.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med etravirin.
English: Lopinavir/Ritonavir (400/100 mg twice daily)
Danish: Ritonavir (100 mg mg to gange dagligt)
English: For use of the 85 mg tablet, please refer to the Summary of Product Characteristics for Vitekta 85 mg tablets.
Danish: Der henvises til produktresuméet for Vitekta 85 mg tabletter for oplysninger om anvendelse af 85 mg tabletten.
English: Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)
Danish: Cobicistat (150 mg én gang dagligt)
English: Tabulated summary of adverse reactions
Danish: Resumé af sikkerhedsprofil
English: The pharmacokinetics of elvitegravir in paediatric subjects have not been established.
Danish: Elvitegravirs farmakokinetik hos børn er ikke klarlagt.
English: No dose adjustment is required when Vitekta is co-administered with famotidine.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med famotidin.
English: Due to inhibition of CYP3A by ritonavir, ketoconazole exposure is increased.
Danish: Eksponering for ketoconazol forhøjes pga. CYP3A-hæmning af ritonavir.
English: Each film-coated tablet contains 150 mg elvitegravir.
Danish: Hver filmovertrukket tablet indeholder150 mg elvitegravir.
English: When used in combination with atazanavir/ritonavir and lopinavir/ritonavir, the dose of Vitekta should be decreased from 150 mg once daily to 85 mg once
Danish: Ved anvendelse i kombination med atazanavir/ritonavir og lopinavir/ritonavir, bør dosis af Vitekta reduceres fra 150 mg én gang dagligt til 85 mg én gang dagligt
English: Nervous system disorders:
Danish: Tegn på osteonekrose er:
English: §Due to inhibition of CYP3A by ritonavir, maraviroc exposure is significantly increased.
Danish: §Eksponering for maraviroc forhøjes signifikant pga.
English: Abacavir: AUC: ↔ Cmax: ↔
Danish: Abacavir: AUC: ↔
English: Tél: + 33 (0) 1 46 09 41 00
Danish: Tél/Tel: + 32 (0) 24 01 35 50
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/883/002
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE)
English: Adverse reaction
Danish: Krydsresistens
English: No dose adjustment is required when Vitekta is co-administered with omeprazole.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med omeprazol.
English: PHARMACOLOGICAL PROPERTIES
Danish: Pædiatrisk population
English: Cambridge
Danish: Warfarin
English: No dose adjustment is required when Vitekta is co-administered with stavudine.
Danish: Dosisjustering er ikke nødvendig, når Vitekta administreres samtidigt med stavudin.
English: Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Danish: Autoimmune lidelser (såsom Graves sygdom) er også rapporteret at forekomme i forbindelse med immunreaktivering.
English: When used in combination with atazanavir/ritonavir and lopinavir/ritonavir, the dose of Vitekta should be decreased from 150 mg once daily to 85 mg once daily (see section 4.2).
Danish: Ved anvendelse i kombination med atazanavir/ritonavir og lopinavir/ritonavir, bør dosis af Vitekta reduceres fra 150 mg én gang dagligt til 85 mg én gang dagligt (se pkt.
English: Frequency
Danish: Diarré
English: Elvitegravir (150 mg once daily) Ritonavir (100 mg once daily)
Danish: Ritonavir (100 mg én gang dagligt)
English: Rosuvastatin: AUC: ↑ 38% Cmax: ↑ 89% Cmin: ↑ 43%
Danish: 25-O-desacetyl-rifabutin: AUC: ↑ 851 % Cmax: ↑ 440 %** Cmin: ↑ 1.836 % sammenlignet med
English: Italia
Danish: España
English: Ísland
Danish: Eesti
English: Protect from frost.
Danish: Beskyttes mod frost.
English: Exp <<EXP month/year>>
Danish: Udløbsdato <<EXP month/year>>
English: Diergeneesk d., deet Iûs,
Danish: Diergeneesk d., deet Iûs, afl.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Per gram:
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Per gram:
English: The use of the product as proposed is not expected to pose a risk for the environment.
Danish: Anvendelsen af lægemidlet som foreslået forventes ikke at udgøre en miljørisiko.
English: Once opened, use by:
Danish: Efter åbning anvendes inden:
English: Powder for administration in drinking water
Danish: Pulver til administration i drikkevand
English: For that purpose wear gloves and a dust mask.
Danish: Bær handsker og støvmaske til dette formål.
English: = .... mg product per litre drinking water
Danish: = .... mg produkt pr. liter drikkevand
English: Since mostly this is caused by overdosage, it is important to measure the dosage accurately.
Danish: Eftersom dette primært skyldes overdosering, er det vigtigt at opmåle doseringen præcist.
English: The medicated milk replacer should be used immediately.
Danish: Den medicinerede mælkeerstatning skal anvendes med det samme.